In 2017, Blum et al. presented a joint efficacy analysis from the three adjuvant ABC trials (US Oncology Research (USOR) 06-090, National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132 and NSABP B-49) and concluded that anthracycline/taxane-based chemotherapy improved invasive DFS in patients with high-risk HER2-negative breast cancer compared to TC6 because the obtained hazard ratio exceeded the prespecified inferiority boundary [9]. The gene discussed is ERBB2; the disease is breast cancer.